Ready-to-use sterile CAR-T cell lines for leukemia research
Amsbio (Oxford, UK) offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for the treatment of children and adolescents with B-cell acute lymphoblastic leukemia (ALL).
Amsbio Business Development Manager – Maja Petkovic commented, “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This success inspired new research that demonstrated CAR-T cell therapy targeting multiple B cell proteins offers improved cancer treatment by reducing tumor recurrence from antigen escape, enhancing anti-tumor efficacy through synergistic recognition, overcoming tumor heterogeneity, and potentially improving treatment specificity.”
Petkovic added, “Our ready-to-use CAR-T cell line portfolio is extensive and growing. It includes knockout cell lines for TCR, B2M, and CIITA, enabling the modelling of universal CAR-T cells. We can also provide sterile, pathogen- and mycoplasma-free cell lines expressing common CAR targets like BCMA, CD19, CD20, CD22 and more, many of which include the luciferase reporter for simple monitoring. Amsbio now can also offer ready-to-use CAR-expressing cells for assay design/optimization and as positive controls in co-culture assays, as well as bispecific CAR T cells targeting CD19 & CD22.
For further information ready-to-use sterile cell lines for CAR-T therapy research please visit https://www.amsbio.com/car-t-cell-research/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].
About Amsbio
Now part of the Europa Biosite group of companies, AMS Biotechnology (Amsbio) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for R&D in the medical, nutrition, cosmetics and energy industries. Amsbio has in-depth expertise in extracellular matrices (ECMs) to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows Amsbio to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, Amsbio offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, Amsbio is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical-grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology and high-quality solutions for viral delivery.
